Traders should watch for the NEO100 interim data readout (~Aug 2026) and NEO212 FDA meeting outcome as key catalysts. Cash runway is tight through Sep 2026, but the PIPE and LOC provide a cushion; any delay in clinical milestones could pressure the stock. CEO insider buying offers some support.
Price Chart
Executive Summary
NeOnc reported Q1 2026 net loss of $8.8M (-$0.38/sh) vs consensus -$0.30, a 26.7% miss, but this is typical for pre-revenue biotechs. Operationally, NEO212 Phase 1 completed with RP2D set, NEO100 Phase 2a fully enrolled with data in Aug 2026, CEO bought >$500k shares, and $10M PIPE + undrawn LOC fund ops into Sep 2026. The stock may trade range-bound near-term with catalyst-driven upside potential.
Key Financial Metrics
Key Facts
- Q1 2026 net loss $8.8M vs $32.3M in Q1 2025, improvement driven by lower stock-based compensation and advisory fees.
- EPS of -$0.38 missed consensus of -$0.30 (26.7% miss).
- Cash and equivalents $138,601 as of March 31, 2026, supplemented by $10M PIPE commitment and $10M undrawn LOC.
- NEO212 Phase 1 complete, RP2D 610 mg, planning Type B End-of-Phase 1 FDA meeting.
- NEO100 Phase 2a fully enrolled for IDH1-mutant HGG, interim data readout expected ~August 2026.
- CEO Amir Heshmatpour purchased >$500k of NTHI shares in open market.
- Normalized cash operating expenses ~$6.1M for Q1 ($24.4M annualized).
Financial Impact
EPS miss of -26.7% vs consensus, but pre-revenue stage; net loss improved 73% YoY to $8.8M.
Risk Factors
- Cash runway only until September 2026; potential dilution from follow-on financing if milestones slip.
- Clinical trial risks: NEO100/NEO212 may fail to show efficacy in larger cohorts.
- EPS miss may weigh on sentiment in the near term given high expectations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-005421 |
| Document: neonctechnologies_ex99-1.htm | 0001829126-26-005421 |
| Document: 0001829126-26-005421-index-headers.html | 0001829126-26-005421 |
| Document: 0001829126-26-005421-index.html | 0001829126-26-005421 |
| Document: 0001829126-26-005421.txt | 0001829126-26-005421 |
| 8-K Data (Synthetic) | 0001829126-26-005421 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 8-K | $2.95 | awaiting T+60 | — | $3.24 (+9.83%) |
Oct 15, 2026 10d ago | 8-K | $2.70 | awaiting T+60 | — | $3.24 (+20.00%) |
Sep 18, 2026 5w ago | Insider Cluster | $3.33 | awaiting T+60 | — | $3.24 (−2.70%) |
Sep 17, 2026 5w ago | 8-K | $3.41 | awaiting T+60 | — | $3.24 (−4.99%) |
Sep 15, 2026 5w ago | Insider Cluster | $2.99 | awaiting T+60 | — | $3.24 (+8.36%) |
Sep 10, 2026 6w ago | 8-K | $3.66 | awaiting T+60 | — | $3.24 (+11.48%) |
Sep 10, 2026 6w ago | 424B5 | $3.66 | awaiting T+60 | — | $3.24 (+11.48%) |
Aug 20, 2026 9w ago | Insider Cluster | $4.68 | awaiting T+60 | — | $3.24 (−30.70%) |
Aug 18, 2026 9w ago | Insider Cluster | $5.53 | awaiting T+60 | — | $3.24 (−41.41%) |
Aug 12, 2026 10w ago | 8-K | $3.46 | awaiting T+60 | — | $3.24 (−6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers